MX2020009478A - Compuestos y sus usos para tratar tumores en un paciente. - Google Patents

Compuestos y sus usos para tratar tumores en un paciente.

Info

Publication number
MX2020009478A
MX2020009478A MX2020009478A MX2020009478A MX2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A
Authority
MX
Mexico
Prior art keywords
compounds
icd
subject
treat tumors
relates
Prior art date
Application number
MX2020009478A
Other languages
English (en)
Inventor
Astrid Zimmermann
Ruiz Maria Jesus Ortiz
Heike Dahmen
Thomas Grombacher
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2020009478A publication Critical patent/MX2020009478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con compuestos que pueden usarse para inducir la muerte celular inmunogénica (ICD). En algunos casos, dos o más compuestos se combinan para inducir la ICD. La invención también se relaciona con la combinación de los compuestos que inducen la ICD con un agente que estimula el sistema inmunológico, tal como un inhibidor del punto de control inmunológico, en particular, para tratar cánceres o inhibir el crecimiento tumoral.
MX2020009478A 2018-03-14 2019-03-13 Compuestos y sus usos para tratar tumores en un paciente. MX2020009478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161849 2018-03-14
PCT/EP2019/056287 WO2019175243A1 (en) 2018-03-14 2019-03-13 Compounds and uses thereof to treat tumors in a subject

Publications (1)

Publication Number Publication Date
MX2020009478A true MX2020009478A (es) 2020-10-22

Family

ID=61655700

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009478A MX2020009478A (es) 2018-03-14 2019-03-13 Compuestos y sus usos para tratar tumores en un paciente.

Country Status (11)

Country Link
US (1) US20210353614A1 (es)
EP (1) EP3765019A1 (es)
JP (1) JP2021517145A (es)
KR (1) KR20200131270A (es)
CN (1) CN111867589A (es)
AU (1) AU2019233596A1 (es)
CA (1) CA3093499A1 (es)
IL (1) IL277158A (es)
MX (1) MX2020009478A (es)
RU (1) RU2020133020A (es)
WO (1) WO2019175243A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3190226A1 (en) * 2020-09-18 2022-03-24 Merck Patent Gmbh Pharmaceutical preparation
TW202412766A (zh) * 2022-09-16 2024-04-01 大陸商應世生物科技（南京）有限公司 Ｆａｋ抑制劑及拓撲異構酶抑制劑的藥物組合及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
MX349463B (es) 2008-09-26 2017-07-31 Univ Emory Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
JP6320756B2 (ja) * 2010-12-06 2018-05-09 キュア キャンサー ワールドワイド エルエルシー 癌を治療するための化学および免疫療法を用いた癌細胞の代謝標的法
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA2926856A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
CN113549159A (zh) 2014-02-10 2021-10-26 默克专利有限公司 靶向TGFβ抑制
WO2016155884A1 (de) 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
JP2018527377A (ja) * 2015-09-16 2018-09-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌の処置におけるトポイソメラーゼ−ｉ阻害剤と免疫療法との組み合わせ
JP2019512512A (ja) * 2016-03-21 2019-05-16 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ シンノリン−４−アミン化合物およびその癌治療への使用
CA3072392A1 (en) * 2017-08-11 2019-02-14 Merck Patent Gmbh Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl]-benzonitrile

Also Published As

Publication number Publication date
US20210353614A1 (en) 2021-11-18
WO2019175243A1 (en) 2019-09-19
RU2020133020A (ru) 2022-04-14
EP3765019A1 (en) 2021-01-20
KR20200131270A (ko) 2020-11-23
CA3093499A1 (en) 2019-09-19
IL277158A (en) 2020-10-29
JP2021517145A (ja) 2021-07-15
AU2019233596A1 (en) 2020-10-08
CN111867589A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
MY185579A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
PH12020550936A1 (en) Combination drug including tlr7 agonist
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
WO2017059319A3 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
WO2018094190A3 (en) Gut microbiota and treatment of cancer
PH12015502855B1 (en) Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations
MY192703A (en) Compositions containing tucaresol or its analogs
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
PH12019501010A1 (en) Arginase inhibitor combination therapies
SG10201900072VA (en) A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2023011105A (es) Virus oncoliticos optimizados y usos de los mismos.
NZ712691A (en) C. novyi for the treatment of solid tumors in humans
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
AU2015279834A8 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
MX2020009478A (es) Compuestos y sus usos para tratar tumores en un paciente.
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.